Alcon is the global leader in eye care with an unparalleled breadth of product offerings in surgical, ophthalmic pharmaceuticals and vision care, serving the full life cycle of patient needs across eye diseases and vision conditions.
From a child's first contact lens for nearsightedness to a grandparent's intraocular lens implantation for cataract correction, Alcon innovations help people of all ages see the world more clearly.
Over the next five years, Alcon plans to invest approximately USD 5 billion to discover and develop new and innovative treatments for vision conditions and eye diseases. This represents the largest commitment to R&D in the eye care industry. Alcon is currently developing products to treat cataracts, glaucoma, age-related macular degeneration, retinal diseases, dry eye, infection, inflammation, ocular allergies, refractive errors and other ocular health issues.
Through the merger of Novartis and Alcon, uniting the strengths of Alcon, CIBA Vision and Novartis Ophthalmics into one eye care business, Alcon has become the second-largest division of Novartis. Alcon now offers the widest spectrum of eye care products in surgical, ophthalmic pharmaceuticals and vision care across 180 markets and runs operations in 75 countries.